

HEOR



Health Economics & Outcomes Research Fellowships

2027-2029

 **NOVARTIS**

Reimagining medicine, together.

©2026 Novartis

1199552-100

Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin novae artes, meaning "new skills," is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.



Purpose

The Health Economics & Outcomes Research (HEOR) Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.



Overview

Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research (HEOR) Fellowship positions for the 2027-2029 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.


While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in dermatology, cardiovascular franchises and renal franchises.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

First-Year Fellowship Sites for 2-Year Programs (3 Positions):

- Baylor Scott & White Health,
The University of Texas at Austin, Austin, TX
(1 position)
- Jefferson College of Population Health,
Thomas Jefferson University, Philadelphia, PA
(1 position)
- University of Pittsburgh School of Pharmacy/
UPMC Health Plan, Pittsburgh, PA
(1 position)

Fellowship Alumni: Where Are They Now?



Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Karishma Thakkar, PharmD, MS
Senior Manager, HE&OR and
HE&OR Fellowship Director
East Hanover, NJ
usheor.fellowship@novartis.com



Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin



Fellowship Sites & Preceptors

Baylor Scott & White Health

Paul Godley, PharmD, FASHP, BCPS, System Director, Specialty Pharmacy, Temple, TX

The University of Texas at Austin College of Pharmacy

Chanhyun Park, PhD, MPharm, MEd, RPh, Assistant Professor of Health Outcomes, Austin, TX

Novartis Pharmaceuticals Corporation

Karishma Thakkar, PharmD, MS, Senior Manager, HE&OR and HE&OR Fellowship Director, East Hanover, NJ
Dipshikha Das, MBA, Director, Evidence Generation Strategy Execution, East Hanover, NJ

Baylor Scott & White Health/The University of Texas at Austin

Baylor Scott & White Health (BSWH) is the largest not-for-profit healthcare system in Texas and an integrated delivery network whose vision is "Empowering You to Live Well." Serving patients across the state through more than 1,300 care sites, including hospitals, clinics, ambulatory, surgery centers, pharmacies and virtual care platforms, BSWH provides approximately 13.6 million patient encounters annually and is supported by more than 7,100 physicians. Beyond direct patient care, BSWH advances population health through the Baylor Scott & White Health Plan and the Baylor Scott & White Quality Alliance (BSWQA), collectively serving more than 1.2 million covered lives through innovative value-based care and accountable care models.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes Division, College of Pharmacy, The

University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and the Fellow pursues a Master of Science degree, funded by the fellowship, in Pharmaceutical Sciences at the University of Texas at Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. In addition, the Fellow has the option to choose from a variety of elective courses that are offered by the University of Texas at Austin.

The coursework is tailored based on individual interests, background and career goals. Additionally, the College is home to TxCORE (Texas Center for Health Outcomes Research & Education), which is a leader in addressing population and individual health through innovative, high-quality research, and education, and serves the community by responding to critical health care issues that impact patients' daily lives. TxCORE combines the strengths of its nationally recognized clinical, pharmacy, social and behavioral, economics, and policy researchers to collect, analyze, and interpret data, and disseminate research findings throughout the many sectors of the health care industry, government, and private sector organizations.

The unique nature of the BSWH integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

Eligibility

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred. Candidates are required to secure a Texas Pharmacy State Board within 120 days from the start date.

Information

For questions or additional information, please contact:

Lena Lebada, PharmD
Health Economics & Outcomes Research Fellow
Email: lena.lebada@bswhealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



First-Year Fellow: Lena Lebada, PharmD

Lena Lebada is a first-year Health Economics and Outcomes Research (HEOR) Fellow with Baylor Scott & White Health and The University of Texas at Austin.

Lena earned her Doctor of Pharmacy degree from Loma Linda University School of Pharmacy. During pharmacy school, she developed a strong interest in HEOR, managed care, real-world evidence, and the use of healthcare data to improve clinical decision-making and patient outcomes. As an AMCP Foundation/Pfizer Oncology Intern with MaxorPlus, Lena conducted research examining adherence to CDK4/6 inhibitor therapy among patients with breast cancer. She evaluated prescription claims and social determinants of health data to identify potential disparities in treatment adherence and presented her research at the AMCP Nexus Annual Conference. This experience strengthened her understanding of oncology outcomes research, pharmacy benefit management, and the role of real-world data in identifying barriers to appropriate medication use.

Lena also co-authored a retrospective cardiology research study published in *Annals of Pharmacotherapy* evaluating intravenous iron utilization among patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. Using electronic medical record data, the study examined commonly used intravenous iron products, dosing patterns, cumulative iron exposure, relevant laboratory parameters, follow-up monitoring, and clinical outcomes. The research characterized real-world treatment patterns and highlighted opportunities to improve the consistency of intravenous iron use with guideline-directed care. In addition to her research experience, Lena served as an AMCP National Chair and as HEOR Chair for the Academy of Managed Care Pharmacy chapter at Loma Linda University. In these roles, she led a team responsible for disseminating current pharmacy news and updates and organizing educational series and teaching sessions focused on medication-use evaluations and healthcare data analysis.

During her first year of fellowship, Lena supports outcomes research at Baylor Scott & White Health while pursuing a Master of Science in Pharmaceutical Sciences at The University of Texas at Austin. Through her fellowship and graduate education, she hopes to strengthen her expertise in real-world evidence generation, research design, healthcare data analysis, and evidence dissemination. Lena ultimately aspires to pursue a leadership career in HEOR and contribute to research that improves the value, quality, and accessibility of patient care.



Second-Year Fellow: Beverly Fuerte, PharmD

Beverly Fuerte is a second-year Post-Doctoral Fellow in Health Economics and Outcomes Research (HEOR) at Baylor Scott & White Health and the University of Texas at Austin in collaboration with Novartis.

She graduated with her Doctor of Pharmacy and Certificate in Healthcare Decisions Analysis from the University of Southern California Mann School of Pharmacy and is currently pursuing a Master's in Pharmaceutical Science Health Outcomes. Prior to fellowship, Beverly has published research investigating the budget impact of pre-emptive pharmacogenomic testing in acute lymphoblastic leukemia. She has also had extensive clinical and administrative experience across a range of health care settings including Kaiser Permanente where she worked in the community setting, and the Los Angeles Department of Health Services where she was involved in projects that oversee cost-avoidance of pharmacist-led protocols for cancer infusions and contribute to Pharmacy & Therapeutics (P&T) formulary decision making.

During her first year of fellowship, Beverly has contributed to research that strives to highlight gaps in care and improve patient outcomes through data-driven insights. She is currently developing manuscripts in her research investigating the cost burden of potential delayed diagnosis of transthyretin amyloid cardiomyopathy, budget impact of cell therapy for type I diabetes, and artificial intelligence (AI) performance in FDA approval predictions in phase-3 oncology clinical trials. Beverly has also received NIH-funded training on data infrastructure to improve health information interoperability and support AI applications in healthcare.

As a second-year fellow, Beverly supports the U.S. HEOR Immunology team by engaging with internal stakeholders to design and execute impactful studies, including retrospective database analyses, systematic literature reviews, budget impact models, and value dossiers for upcoming pipeline product launches and investigations.

Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health



Fellowship Sites & Preceptors

Thomas Jefferson University

Vittorio Maio, PharmD, MS, MSPH, Professor and Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

Novartis Pharmaceuticals Corporation

Karishma Thakkar, PharmD, MS, Senior Manager, HE&OR and HE&OR Fellowship Director, East Hanover, NJ
Dipshikha Das, MBA, Director, Evidence Generation Strategy Execution, East Hanover, NJ

College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of eleven colleges that comprise Thomas Jefferson University, which was founded in 1824 as Jefferson Medical College. JCPH builds on the 18-year history of Jefferson's Department of Health Policy and specializes in key areas of population health, public health, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College offers one of the oldest and most established outcomes research fellowship programs in the country. To date, more than 80 individuals have completed JCPH Fellowships and successfully pursued careers across all sectors of the healthcare industry, including government, pharmacy, insurers, and consulting.

During the first year, the Fellow will work at JCPH on the University's Center City campus in Philadelphia and will be assigned to manage specific outcomes research projects. As a member of the JCPH research team, the Fellow will have opportunities to attend and present at research meetings, journal clubs, and sponsored educational programs. The Fellow may also contribute to graduate-level courses taught by JCPH faculty in the College's public health, AHEOR, health data science, and population health graduate programs. The Fellow will have the opportunity to refine scientific writing skills by authoring abstracts and manuscripts, with the possibility of publication in the American Journal of Medical Quality and Population Health Management.

Networking is also an important component of the first year. The Fellow will interact with decision-makers both within the University and across a broad variety of organizations, including pharmaceutical and medical device manufacturers, health plans, and other health-related employers. The Fellow will meet regularly with JCPH faculty and staff to discuss research projects and academic experiences, and will be assigned a faculty mentor who will provide guidance and support throughout the first year. Completion of master-level coursework through JCPH is a formal component of the Fellowship and helps develop the knowledge and skills required for health economics and outcomes research. The Fellow will have the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, health data science, or applied health economics and outcomes research.

The second year of training will take place at Novartis, in East Hanover, New Jersey. Under the guidance of a Novartis preceptor, the Fellow will work directly with the HEOR department at Novartis to advance their educational objectives and gain applied experience in health economics and outcomes research. In addition to completing project work, the Fellow will participate in meetings to present and discuss their work and further develop their networking and presentation skills.

Eligibility


Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

Information

For questions or additional information, please contact:

Wei Yi Kong, PhD, MA
Health Economics & Outcomes Research Fellow
Email: weiyi.kong@jefferson.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



First-Year Fellow: Wei Yi Kong, PhD, MA

Wei Yi Kong is a first-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health and Novartis Pharmaceuticals Corporation.

She holds a Doctor of Philosophy in Health Behavior from the University of North Carolina at Chapel Hill, Gillings School of Global Public Health, where she grew her research portfolio in clinician-parent communication about adolescent human papillomavirus vaccination. Her portfolio reflects her methodological expertise with systematic review, national survey, web-based experiments, and qualitative interviews. After completing her doctoral training, she joined Mayo Clinic as a Research Associate in the Division of Epidemiology and led several human papillomavirus cancer prevention and control projects analyzing nationally representative survey data, electronic health records, and cluster randomized trial data. With more than 20 peer-reviewed publications to date, she has published extensively including in flagship and highly influential journals, such as *Academic Pediatrics*, *JAMA Network Open*, and *Journal of Adolescent Health*. Her research examines human papillomavirus cancer disparities and identifies potential solutions to improve equitable health outcomes, which contributed to her interest in integrating health economics and health equity to meaningfully impact population health.

In the first year of her fellowship, Wei Yi is supporting multiple projects assessing the cost-effectiveness of partial nephrectomy procedures, economic outcomes of patient-directed discharge, and clinician experiences with managing healthcare associated infections. She is currently pursuing a Master's degree in Applied HEOR at the Jefferson College of Population Health.



Second-Year Fellow: Vietbao Phan, PharmD

Vietbao Phan (Bao) is a Post-Doctoral HEOR Fellow at the Jefferson College of Population Health and Novartis Pharmaceuticals Corporation.

He earned his Doctor of Pharmacy from Jefferson College of Pharmacy and is currently pursuing a Master of Science in Applied HEOR. Prior to the fellowship, Bao contributed to a scoping review on psychosocial interventions for pregnant women with opioid use disorder and a systematic review on patient preferences for medication-assisted treatment. During his first year, he co-authored a retrospective NIS analysis comparing perioperative outcomes and costs across partial nephrectomy techniques for renal cell carcinoma, and a commentary outlining four strategies to advance pharmaco-equity in medication access. Building on the NIS analysis, he developed a decision-tree cost-effectiveness model evaluating the comparative value of three surgical techniques. He also contributed to a cross-sectional study applying the EQ-5D-5L to estimate health utility weights in perinatal women with opioid use disorder. Additionally, he contributed to a mixed-methods analysis of smartphone app preferences and willingness to pay among perinatal women with OUD, and a qualitative study examining infection prevention challenges across 18 U.S. hospitals during the COVID-19 pandemic.

As he transitions into Year 2, Bao will be supporting the Neuroscience team at Novartis. He plans to engage with internal and external stakeholders to carry out studies such as literature review, retrospective claims analysis, budget impact analysis, and AMCP dossier development. Overall, he aims to create impactful deliverables and make meaningful connections.

Novartis Pharmaceuticals Corporation/ University of Pittsburgh School of Pharmacy/ UPMC Health Plan (1 position)



Fellowship Sites & Preceptors

University of Pittsburgh School of Pharmacy

Kangho Suh, PharmD, PhD, Assistant Professor, Department of Pharmacy & Therapeutics, Pittsburgh, PA

UPMC Health Plan

Chester "Bernie" Good, MD, MPH, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, Pittsburgh, PA

Samuel Peasah, PhD, RPh, MBA, Director, Center for Value-Based Pharmacy Initiatives and Adjunct Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Novartis Pharmaceuticals Corporation

Karishma Thakkar, PharmD, MS, Senior Manager, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

Dipshikha Das, MBA, Director, Evidence Generation Strategy Execution, East Hanover, NJ

The University of Pittsburgh School of Pharmacy/UPMC Health Plan

UPMC Health Plan, headquartered in Pittsburgh, Pennsylvania, is among the nation's fastest-growing health plans. It is owned by the University of Pittsburgh Medical Center (UPMC), a world-renowned integrated health care delivery and financing system. The UPMC Health Plan is committed to providing its members better health, through an evidence-based insurance design and generous pharmacy benefit. The Center for High-Value Healthcare (CHVHC) is a nonprofit research organization housed within UPMC Health Plan that translates, through research and collaboration, the work of the UPMC Insurance services into evidence-based practice and policy change. The Center for Value-based Pharmacy Initiatives is a center within CHVHC that focuses on value/outcomes-based contracts and pharmacy-related outcomes research in collaboration with the pharmacy department of the Health Plan and other external partners.

University of Pittsburgh is one of the oldest institutions of higher education in the United States. It was ranked as the No. 1 public university in the Northeastern United States in 2020 and is ranked in the top 20 among the nation's top public colleges

and universities. At the School of Pharmacy, the Fellow will have the opportunity to earn an online Master of Science in PharmacoAnalytics – Pharmaceutical Outcomes Research. This program provides students with tools and skills necessary to analyze large healthcare datasets and apply data analytic and pharmacoepidemiology concepts to enhance pharmaceutical use and outcomes. In the first year of the Master's program, the Fellow will take asynchronous online courses with regularly scheduled synchronous touchpoints related to study design, data collection, data management, data organization, data analysis, and data visualization/communication. Beginning in the summer of the second year, the Fellow will work with Dr. Suh to identify a thesis topic, develop the thesis over the course of the year, and defend it in the spring semester.

The intersection of managed care, academia, and opportunities to lead outcomes research projects will enable the Pitt Pharmacy and UPMC Health Plan 1st year site to equip the fellow with the necessary skills and abilities to succeed in the 2nd year at Novartis and beyond.

Eligibility


Eligible candidates must have a doctorate in pharmacy. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

Information

For questions or additional information, please contact:

Weiming (Ariel) Dong, PharmD
Health Economics & Outcomes Research Fellow
Email: ARD469@pitt.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



First-Year Fellow: Weiming (Ariel) Dong, PharmD

Weiming (Ariel) Dong is a first-year Health Economics & Outcomes Research (HEOR) fellow with Novartis Pharmaceutical Corporation, the University of Pittsburgh, and University of Pittsburgh Medical Center (UPMC) Health Plan.

Ariel received her Doctor of Pharmacy degree from the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences. Her interest in HEOR began during her first year of pharmacy school through participation in the Pharmacy and Therapeutics competition, which sparked a lasting passion for using health economic modeling and data analytics to help answer the questions healthcare decision-makers frequently face. She worked on a cost-utility analysis evaluating Calcitonin Gene-Related Peptide monoclonal antibodies for the prevention of episodic migraine, presented the work at ISPOR, and published the findings in the journal *PharmacoEconomics*. During pharmacy school, she also served as the President of the Academy of Managed Care Pharmacy (AMCP) student chapter at UCSD, where she helped grow student interest in managed care and health outcomes research. Through a summer internship at Centene Corporation, she gained hands-on exposure to the managed care space and deepened her understanding of the broader healthcare system.

During her first year, Ariel will contribute to various research projects at the University of Pittsburgh and UPMC Health Plan's Center for High-Value Health Care (CHVHC), gaining experience in healthcare utilization analysis, value-based contract design, and economic modeling. She is also pursuing a master's degree in PharmacoAnalytics – Pharmaceutical Outcomes Research. Ariel is excited to build her knowledge in HEOR through the combined strengths of managed care, academia, and industry throughout the fellowship.



Second-Year Fellow: Steven Do, PharmD

Steven Do is a second-year Health Economics and Outcomes Research (HEOR) Fellow at Novartis Pharmaceuticals Corporation in collaboration with the University of Pittsburgh School of Pharmacy and University of Pittsburgh Medical Center (UPMC) Health Plan.

Steven received his Doctor of Pharmacy degree with a named option in Operations and Technology Management from the University of Wisconsin – Madison. His interest in HEOR stems from his background in health outcomes research and quality improvement projects. During pharmacy school, Steven contributed to several outcomes research projects, including an analysis using national administrative data to evaluate the impact of a pharmacist-led chronic obstructive pulmonary disease transitions-of-care program on patient outcomes, quality of care, and access to care. His work has been presented at the Annual Conference on the Science of Dissemination and Implementation in Health and the American Thoracic Society International Conference.

During his first year at the University of Pittsburgh and UPMC Health Plan, Steven designed and led administrative claims analyses evaluating adalimumab biosimilar switching patterns, atopic dermatitis medication utilization, and the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) utilization and chronic disease prevalence. He was also involved in the development of value-based contract concepts across various therapeutic areas. In collaboration with other Novartis fellows, Steven completed a cost-effectiveness analysis evaluating calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine prevention among patients with chronic migraine. He is currently completing his Master of Science in PharmacoAnalytics – Pharmaceutical Outcomes Research at the University of Pittsburgh.

In his second year at Novartis, Steven supports the U.S. HEOR Oncology team. He collaborates cross-functionally with internal and external stakeholders to design and execute real-world evidence studies that address evidence gaps and inform clinical decision-making. His current work includes retrospective database analyses and other outcomes research initiatives that support HEOR tactics and evidence-generation priorities.

Previous Fellows

Neetu Agashivala, MS

Executive Director, Head of Global HEOR,
BioMarin

Adaeze Amaefule, PharmD, MS

Associate Director HEOR,
Disc Medicine

Lauren Bartolome, PharmD, MS

Director, HEOR I&I,
Pfizer

Kelly Fee Bell, PharmD, MSPhr

US RWE & Health Outcomes
GlaxoSmithKline

William Boyko, PharmD

Pharmacist Consultant,
P&C Pharma

Cat Bui, PharmD, PhD

Senior Director, Oncology HEOR Strategy,
AbbVie

Scott Bull, PharmD

Director, Clinical Project Scientist,
Johnson & Johnson Innovative Medicine

Beilei Cai, PhD, MA

Senior Director, HEOR - Cardiovascular,
Novartis

Aaron Carabajal-Johnson, PharmD, MS

Associate Director, Global Health Economics & Outcomes
Research - Cardiovascular,
Bristol Myers Squibb

Swetha Challagulla, MS

Director, Global HEOR Hematology,
BeOne

Cindy Chan, PharmD, MHI, MS

Senior Manager, HEOR Product Lead,
Novartis

Jane Chang, MPH

Senior Director, Value & Evidence Lead, GU Cancer,
Pfizer

Michelle Choi, PharmD

Senior Medical Science Liaison-Immunology,
Kymera Therapeutics

Paul C. Cockrum, PharmD, DPh

Lead, US Health Outcomes Field Team,
Vera Therapeutics, Inc.

Arijita Deb, PhD

Director, Value Evidence and Outcomes,
GlaxoSmithKline

Laurence Djatche, PharmD, MS

Global Health Economics & Value Assessment Business Partner,
Sanofi

QuynhChau Doan, PhD, RPh, MS

Director, Health Systems & Outcomes,
Intercept Pharmaceuticals

Joseph Doyle, RPh, MBA

Retired

Batul Electricwala, PhD

Director, HEOR,
Novartis

Raquel Skyla Erb, PharmD, MS

Senior Researcher, Health Outcomes,
Arine

John Fastenau, PhD, MPH, RPh

Executive Director, Health Economics Outcomes Research,
Insmmed Incorporated

Feride Frech, PhD, MPH

Senior Director, HEOR & RWE,
Eisai, Inc.

Rahul Garg, PhD

Director of Evaluation and Outcomes Assessment,
Alabama College of Osteopathic Medicine

Joseph Goble, PharmD, MS

Director, National Accounts, Value & Evidence Scientific
Engagement,
Johnson & Johnson Innovative Medicine

Boris Gorsh, PharmD, MS

Sr. Director, Global Oncology HEOR and RWE,
Daiichi Sankyo, Inc.

Geneen Graber Maxwell, PharmD

President and CEO,
Dr. G's Pharmacy

Bill Grant, PhD

Professor of Economics, College of Business,
James Madison University

Amy Grogg, PharmD

Strategic Advisor,
Vesey Street Capital Partners

Kristy Hanson, PharmD, MS

Scientific Consultant, Value Demonstration,
United BioSource Corporation:
An Express Scripts Company

Peter Hur, PharmD, MBA

Director, Worldwide HEOR Oncology,
Pfizer

Archie Jackson, PharmD

Chief Operating Officer,
A&S Healthcare Consulting and Analytics, Inc.

Tom Karagiannis, PharmD, MS

Director, Market Access Immunology - Europe,
AbbVie

Jennifer Kim, PharmD

Director, Global Pricing and Market Access,
AstraZeneca

John Kim, PharmD

Executive Director, Head of Global Market Access,
Seagen

Nina Kim, PharmD, MS

Associate Director, Real World Value & Evidence, Oncology,
Johnson & Johnson Innovative Medicine

Mumbi Kimani, PhD, MS

Associate Director, HEOR Product Lead,
Novartis

Yoona Kim, PharmD, PhD

Co-founder and CEO,
Arine

John Ko, PharmD, MS

Global Medical Affairs Lead (Liver),
Beam Therapeutics

Amy Law, PharmD, MS

Director, HTA, Value & Evidence,
Pfizer

Junji Lin, PhD

Director, Global HEOR - Cardiovascular,
Bristol Myers Squibb

Jackie Lu, PharmD, MS

Business Strategy Consultant,
Merry Life Biomed

Mario Luong, PharmD, MPH

Director of Operations,
Optum

Shilpa Mehta, PharmD

AVP, Global Oncology Portfolio Lead - Merck | Daiichi Sankyo
Collaboration,
Merck & Co, Inc

Jeannie Menz, PharmD

Freelance

Laetitia N'Dri, PharmD, MS

Associate Director, Value & Implementation, Outcomes Research,
Merck

Gilbert C. Ngan, PharmD

Pharmacist: Part B Policy Analyst,
CMS

Cindy Nguyen, PhD, RPh, MS

Senior Associate Director, HEOR Value Evidence and
Outcomes Liaison,
Boehringer Ingelheim

Jennifer Nguyen, PharmD, MS

Associate Director, US HEOR Oncology/Radioligand Therapies,
Novartis

Lina Nol-Heiring, BS, MBA

Senior Therapeutics Sales Specialist,
LEO Pharma

Engels Obi, PhD

Director, Global CORE - Oncology,
Genmab

Grace Oh (Chun), PharmD

Associate Director, US Medical Promotional Review - Oncology,
Bristol Myers Squibb

Jacqueline B. Palmer, PharmD, MBA

Director, Professional Promotions Marketing,
Novartis

Jina Park, PharmD

Chief Strategy Officer,
AIRS Medical

Natalie (Siyeon) Park, PharmD, MS

Chief Product Officer,
TJM Labs

Shivangi Patel, PharmD, MS

Associate Director, Global Health Economics & Outcomes
Research - Cardiovascular,
Bristol Myers Squibb

Hoa T. Pham, PharmD

Senior Director, Field HEOR,
Beigene

Ngan Pham, PharmD, MS

VP Segment Strategy, Partnerships,
Komodo Health

Craig Plauschinat, PharmD, MPH

Director, HEOR & RWE,
Eisai, Inc.

Shibani Pokras, MPH

Senior Director, Global RWE & Health Outcomes Lead, Vaccines,
GlaxoSmithKline

Karim Prasla, PharmD, MS

Vice President, Clinical Outcomes, Analytics, and Reporting,
Prime Therapeutics

Karina Raimundo, BS Pharmacy, MS

Senior Director Evidence Business Partner,
Genentech, Inc.

David Ray, PharmD, MBA, MPH

Vice President, Integrated Evidence Generation,
Karyopharm Therapeutics, Inc.

Seon Young Ryu, PharmD

Mom/Independent Consulting,
Previously at Genentech

Rahul Sasané, PhD, MS, BPharm

Head - Global Value and Access,
Cerevel Therapeutics, LLC

Veronica Sendersky, PharmD

Managing Director,
Excellentia Pharma Consulting

Amishi Shah, PharmD

Associate Director, Medical Strategy, Imbruvica,
Abbvie

Hemal Shah, PharmD

President/Founder,
Value Matters, LLC

Karisha Shelley, PharmD, MS

Director, Health Economics & Outcomes Research (HEOR) - Global
Oncology,
Bristol Myers Squibb

Slaven Sikirica, MS

HEVA Business Partner - Immunology,
Sanofi

Anh Singhania, PharmD

Head, Health Value Evidence & Outcomes, Medical Affairs,
Alfasigma

Bhavini Patel Srivastava, MS, BS Pharmacy

Director, HEOR,
AbbVie

Liz Stanley Smart, MPH

Global HEOR Lead, Eye Health,
Boehringer Ingelheim

Kangho Suh, PharmD, PhD, MS

Assistant Professor,
University of Pittsburgh

Dusica Tasic, MS, BS Pharmacy

Health Economics Manager,
GE Healthcare

Devi Thaker, PharmD, MS

Director, PharmacoAnalytics,
Express Scripts

Karishma Thakkar, PharmD, MS

Senior Manager, HEOR Product Lead
Novartis

Ryan Thaliffdeen, PharmD, RPH, MS

Associate Director, Global Value & Access, GHEOR Oncology -
Lung (NSCLC, SCLC),
Gilead Sciences

Melody Tran, PharmD, MS

Medical Outcomes Liaison,
Abbott Laboratories

Yuen Tsang, PharmD, MPH

US HEOR Oncology Lead,
Takeda

Charlene Tugwete, PharmD, MS

Manager, Global Health Economics & Outcomes Research Strategy,
AbbVie

Stuart Turner, MPH, BS Pharm

Head, US HE&OR & RWE,
Ipsen

Stefan Varga, PharmD, MS

Senior Director, Medical Affairs Strategy,
Bristol Myers Squibb

Ashok Vegesna, PharmD, MS

Director, Market Access Strategy - Breast & Women's Cancer,
Novartis

Joel Wallace, PharmD, MBA, MPH

Head, Market Access Japan,
Viastris

Alexandra Wallem, PhD, RPh, MS

Advisor: Research Scientist and Analyst,
Eli Lilly

Xiaoxia (Summer) Wang, PharmD, PhD, MS,

Associate Director, RWD Oncology,
Merck

Pin Xiang, PharmD, MS, MBA

Director of HEOR Value Demonstration - CNS,
Boehringer Ingelheim

Esther Yi, PharmD, MS

Director, Value & Evidence, Inflammation and Immunology Pipeline/
Business Development,
Pfizer

Krista Yokoyama, PharmD

Senior Manager, Pharmacy Analytics,
Blue Shield of California

Jing Yuan, PhD

Associate Professor,
Fudan University

HEOR Fellowship Application Form

Please type or print

Date: _____

Name: _____

Last

First

MI

Address: _____

Street

City

State

Zip Code

Phone: _____

Primary

Secondary

Email: _____

Undergraduate and Graduate Degree(s) (date received or expected):

2-Year Programs (Preferred Degrees: PharmD, PhD, MS)

Please rank and check any site(s) of interest:

_____ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation

_____ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

_____ University of Pittsburgh School of Pharmacy/UPMC Health Plan/Novartis Pharmaceuticals Corporation

Application Process (rolling submission, application deadline is October 9th, 2026 at 11:59 pm EDT):

To apply, please email usheor.fellowship@novartis.com and include the following materials:

- Cover Letter
- Application form with first-year fellowship site(s) preference
- CV
- Email addresses for 2 references

If offered an interview, the following documents will be requested:

- 2 Letters of Recommendation (sent via email from references)
- Unofficial Transcript

Requirements:

Graduate degree in a relevant discipline focused on pharmacy, health services research, health economics, epidemiology, or a related discipline (e.g., PharmD, PhD, MPH, etc.). A background in pharmacy or medicine and experience in outcomes research, health economics, or another related field of research is preferred. Excellent communication skills (oral and written). Demonstrated success in working in teams and independently.

Please email or send the required application materials to:

Karishma Thakkar, PharmD, MS
Senior Manager, HE&OR and HE&OR Fellowship Director
Email: usheor.fellowship@novartis.com



Reimagining medicine, together.

Novartis Use Only | Date Received _____